Ricky Hopson Sells 1,401 Shares of Catalent, Inc. (NYSE:CTLT) Stock

Catalent, Inc. (NYSE:CTLTGet Free Report) insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Catalent Stock Up 0.3 %

Shares of NYSE:CTLT opened at $56.39 on Friday. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The firm’s 50 day moving average price is $55.74 and its 200 day moving average price is $51.99. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of -9.24, a price-to-earnings-growth ratio of 5.80 and a beta of 1.20.

Catalent (NYSE:CTLTGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. As a group, equities research analysts predict that Catalent, Inc. will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CTLT. Lindbrook Capital LLC lifted its stake in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Catalent during the 3rd quarter worth approximately $28,000. GAMMA Investing LLC acquired a new position in shares of Catalent in the 4th quarter valued at $33,000. Cary Street Partners Investment Advisory LLC grew its position in shares of Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares during the last quarter. Finally, Rakuten Securities Inc. purchased a new position in shares of Catalent in the 4th quarter valued at $46,000.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. StockNews.com began coverage on Catalent in a research note on Thursday. They set a “sell” rating on the stock. Finally, Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Catalent presently has a consensus rating of “Hold” and a consensus price target of $53.14.

Read Our Latest Stock Analysis on Catalent

Catalent Company Profile

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

See Also

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.